Upcoming Event PRESS Home Media Library Press All information about the IZB – the press area +++ Biotech report by vfa: Biopharmaceuticals successfully gain market share ++++++ Preclinical efficacy and safety data for ViGeneron’s innovative approach to the treatment of Retinitis Pigmentosa ++++++ MPI of Biochemistry: Nature publication addressing the “dark matter” of proteomics ++++++ Non-nutritive sweeteners may affect the human immune system ++++++ LMU Hospital’s annual reception returned this year with exciting topics and a multimedia “magic show” ++++++ Invitris receives 250,000 EUR to complete spin-out from TUM ++++++ Eisbach starts phase I clinical trial with COVID-19 antiviral ++++++ IZB Connects with Shanghai Zhangjiang Hi-Tech Park ++++++ Specific packaging of DNA affects cell division ++++++ Tubulis Enters Strategic Partnership with BMS ++++++ Insempra launches its first functional component for consumer goods ++++++ ERC Advanced Grant of nearly 2.1 million euros for Prof. Dr. Brenda Schulman ++++++ Vivoryon Therapeutics gives update on clinical development of its lead candidate against Alzheimer’s Disease ++++++ Secarna Pharmaceuticals and SciNeuro Pharmaceuticals form partnership ++++++ adivo expands into new headquarters as first clinical study begins ++++++ Thermosome’s Lead Program THE001 receives regulatory approval for first-in-human trial ++++++ Construction of the “New Hauner” at the Grosshadern Campus has started ++++++ Insempra names new Chief Operating Officer ++++++ Training events for project managers and biological safety officers ++++++ The zebrafish brain as a map ++++++ MorphoSys stops proprietary pre-clinical research programs and further optimizes cost structure ++++++ Innovation and Start-up Center Biotechnology (IZB) welcomes Invitris ++++++ When life begins too early ++++++ US-based Neuron23 starts Phase 1 clinical trial in Parkinson’s Disease ++++++ Expansion of the Munich “science line” has started ++++++ Enno Spillner to join Formycon as CFO +++ Registration for the IZB Newsletter IZB at the media Facts & Figures about the IZB Biotech report by vfa: Biopharmaceuticals successfully gain market share Preclinical efficacy and safety data for ViGeneron’s innovative approach to the treatment of Retinitis Pigmentosa Max Planck Institute of Biochemistry: Nature publication addressing the “dark matter” of proteomics Non-nutritive sweeteners may affect the human immune system Contact Person Susanne Simon Phone.: +49 (0)89 - 55 279 48 17 ed.enilno-bzi@nomis IZB press photos IZB press photosCommemorative publication of the IZBRestaurant Seven and More press photosCampus hotel press photos Selection of media reports about the IZB Commemorative publication – 25 years IZB ... The IZB press kit for download To the current press releases 27. April 2023Innovation and Start-up Center Biotechnology (IZB) welcomes LEON20. April 2023Tubulis Enters Strategic Partnership with BMS16. March 202316th Biotech Press-Lounge at the IZB: A new “atlas for human heart cells” may lead to customized and personalized therapies in the future The logos of the IZB for download:
